Skip to content
Screener

CytomX Therapeutics CTMX Shares (Diluted)

Shares (Diluted) at other companies

Pfizer logo
PfizerPFE
5.7B-0.1%
Amgen logo
AmgenAMGN
544M+0.6%
Janux Therapeutics logo
Janux TherapeuticsJANX
62.9M+1.7%
Immunome logo
ImmunomeIMNM
113.3M+30.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
126.1M+18.4%
CTO
Citius Oncology, Inc.CTOR
100M+39.8%

Other financials

Income statement

See full
Revenue$1.4M-92.4%
Operating income-$23.8M-1,749%
Net income-$20.7M-13,319%
EPS (diluted)-$0.09—

Balance sheet

See full
Cash & equivalents$17.2M-64.9%
Total debt$5.7M-17.2%
Total equity$302.1M+152%
Total assets$381.2M+118%

Cash flow

See full
Operating cash flow-$18.1M-14.7%
CapEx--100%
Free cash flow-$18.1M-14.5%

Valuation

See full
Market cap$753.93M+97.9%
Enterprise value$742.41M+119%
P/S41.2×+38.5×

Profitability

See full
Operating margin-476.2%-507pp
Net margin-435.2%-469pp
FCF margin-450.7%-524pp

Returns & leverage

See full
Return on equity-37.8%—
Debt / equity0×0.0×
Current ratio9.4×+5.2×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337950
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Unrealized gain (loss) on investments, net of tax(298)34(307)6
Total comprehensive income (loss)$(20,964)$(120)$(39,221)$23,377
Net income (loss) per share:
Basic$(0.09)$(0.00)$(0.20)$0.22
Diluted$(0.09)$(0.00)$(0.20)$0.21
Shares used to compute net income (loss) per share
Basic218,939,423129,075,546198,221,312108,214,373
Diluted218,939,423129,075,546198,221,312108,928,284

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is CytomX Therapeutics's shares (diluted)?
CytomX Therapeutics (CTMX) reported shares (diluted) of 218.9M in Q2 2026.
How has CytomX Therapeutics's shares (diluted) changed year-over-year?
CytomX Therapeutics's shares (diluted) increased by 69.6% year-over-year, from 129.1M to 218.9M.
What is the long-term trend for CytomX Therapeutics's shares (diluted)?
Over 4 years (2021 to 2025), CytomX Therapeutics's shares (diluted) has grown at a 19.3% compound annual growth rate (CAGR), from 256.5M to 519.2M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about CytomX Therapeutics's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude